Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 2/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.31 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24929574 | 0.98 | CSNK2A1 (0.36) | CSNK2A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24928675 | 0.85 | BRD4 (0.31) | BRD4 | |
| SCHEMBL24929568 | 0.83 | BRD4 (0.33) | BRD4ADRA1ATDO2 | |
| SCHEMBL24930072 | 0.77 | BRD4 (0.46) | PDE4APDE4BPDE4CPDE4DBRD4 | |
| SCHEMBL23850721 | 0.70 | ALDH1A1 (0.40) | LMNAMAPTKMT2AL3MBTL1 | |
| SCHEMBL24928863 | 0.69 | CSNK2A1 (0.36) | CSNK2A1CHEK1 | |
| SCHEMBL30845563 | 0.68 | CSNK2A1 (0.42) | CSNK2A1LMNAMAPTKMT2AL3MBTL1 | |
| SCHEMBL24928857 | 0.68 | CSNK2A1 (0.42) | CSNK2A1LMNAMAPTKMT2AL3MBTL1 | |
| SCHEMBL22636625 | 0.67 | ALDH1A1 (0.36) | LMNAMAPTKMT2AL3MBTL1TDO2 | |
| SCHEMBL24930069 | 0.67 | CSNK2A1 (0.39) | CSNK2A1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376046-A1 | PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2024-11-14 | — | — | US | disclosed |
| EP-4376955-A1 | PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2024-06-05 | — | — | EP | disclosed |
| CN-117881657-A | Phenyl-sulfamoyl-benzoic acid derivatives as ERAP1 modulators | 格雷沃尔夫治疗有限公司 | 2024-04-12 | — | — | CN | disclosed |
| WO-2023007188-A1 | PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023007188-A1 | PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376046-A1 | PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS | ERAP1, XPO1, RRP15 | CSNK2A1 503/4885PDE4A 4638/4885PDE4B 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.